Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.62 |
| ▸ | KIF5B | P33176 | 5/20 | 0.62 |
| ▸ | KDR | P35968 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 10/20 | 0.56 |
| ▸ | EGFR | P00533 | 6/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.55 |
| ▸ | ABL2 | P42684 | 5/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020339 | 0.90 | RET (0.66) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL13020345 | 0.87 | SRC (0.56) | SRCEGFRRIPK2 | |
| SCHEMBL13840215 | 0.86 | SRC (0.73) | SRCEGFRABL1ABL2 | |
| SCHEMBL13020346 | 0.86 | RET (0.52) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL13020342 | 0.83 | SRC (0.56) | KDRSRCEGFRABL1ABL2 | |
| SCHEMBL14706449 | 0.81 | FGFR4 (0.71) | KDRSRCEGFR | |
| SCHEMBL13020005 | 0.81 | SRC (0.78) | RETKIF5BKDRSRCEGFR | |
| SCHEMBL13020153 | 0.80 | SRC (0.58) | RETKDRSRCEGFRABL1 | |
| SCHEMBL13020343 | 0.79 | SRC (0.59) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL3788920 | 0.79 | EGFR (0.56) | KDRSRCEGFRABL1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | RET 3063/4885KIF5B 29/4885KDR 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.